AEterna Zentaris Inc. (AEZS)

[chmcnfunds]

Rumors about leaked data, but the tangible likely reason for the pop:
_______________________________________________
Details of Maxim Group Buy Rating on AEterna Zentaris (USA) (AEZS)

Posted by Eamon Howard | Jan 17, 2017

AEterna Zentaris (USA) (AEZS) was Reiterated by Maxim Group to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 10 from a previous price target of $7 . Maxim Group advised their investors in a research report released on Jan 17, 2017.

AEterna Zentaris (USA)

AEterna Zentaris (USA) opened for trading at $2.5 and hit $2.6 on the upside on Friday, eventually ending the session at $2.55, with a gain of 4.08% or 0.1 points. The heightened volatility saw the trading volume jump to 1,92,727 shares. Company has a market cap of $30 M.

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology endocrinology and women’s health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH based in Frankfurt Germany Zentaris IVF GmbH a direct wholly owned subsidiary of AEZS Germany based in Frankfurt Germany and Aeterna Zentaris Inc. Its drug development efforts are focused on two compounds zoptarelin doxorubicin and Macrilen which are in clinical development and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates) which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.
_____________________________________________
https://www.highlandmirror.com/details-of-maxim-group-buy-rating-on-aeterna-zentaris-usa-aezs/

(I have no shares)

AEZS